Sept 10 (Reuters) - BridgeBio Pharma ( BBIO ) said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland. The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment. (Reporting by Puyaan Singh; Editing by Shinjini Ganguli)...

05:00 PM EDT, 09/10/2024 (MT Newswires) -- Ric Smith, Chief Product & Technology Officer, on September 06, 2024, sold 51,052 shares in Sentinelone ( S ) for $1,140,682. Following the Form 4 filing with the SEC, Smith has control over a total of 585,647 shares of the company, with 585,647 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1583708/000158370824000078/xslF345X05/wk-form4_1726001520.xml ...

05:02 PM EDT, 09/10/2024 (MT Newswires) -- Westaim ( WEDXF ) after trade Tuesday said it sold all its remaining 1.91-million shares in Skyward Specialty Insurance Group. The investment-holding company said proceeds, less commissions, were approximately US$79 million. Westaim's ( WEDXF ) remaining investments include significant interests in Arena and the Arena FINCOs. The company's shares closed down $0.04 to...

05:10 PM EDT, 09/10/2024 (MT Newswires) -- Samir Desai, Executive Vice President, Chief Digital & Technology Officer, on September 06, 2024, sold 19,041 shares in Abercrombie & Fitch ( ANF ) for $2,501,264. Following the Form 4 filing with the SEC, Desai has control over a total of 27,985 shares of the company, with 27,985 shares held directly. SEC Filing:...